Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued to investors on Friday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

EGRX stock opened at $0.71 on Friday. Eagle Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $6.81. The firm’s fifty day moving average is $1.21 and its 200 day moving average is $3.42.

Hedge Funds Weigh In On Eagle Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in EGRX. Perceptive Advisors LLC bought a new stake in Eagle Pharmaceuticals in the 2nd quarter worth $971,000. Vanguard Group Inc. grew its holdings in Eagle Pharmaceuticals by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock worth $3,358,000 after acquiring an additional 2,630 shares during the last quarter. Creative Planning bought a new stake in Eagle Pharmaceuticals in the 3rd quarter worth $59,000. Price T Rowe Associates Inc. MD bought a new stake in Eagle Pharmaceuticals in the 1st quarter worth $83,000. Finally, Fidelis Capital Partners LLC bought a new stake in Eagle Pharmaceuticals in the 2nd quarter worth $71,000. Institutional investors own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.